Notably, ZNF322AHigh/c-MycLow expression profile in tumor specimen serves as an independent prognosis marker for poor outcome of lung cancer patients who may be considered for treatment strategy using mitochondria-targeting agents or HDAC3 inhibitors. Here, HDAC3 is linked to neoplasm.